Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06236087 · ClinicalTrials.gov registry record
Overdose Prevention Centers and Behavioral Health
A clinical trial, sponsored by NYU Langone Health.
- Not yet
- Registry status
- 500
- Enrollment target
NCT06236087: Clinical Trial study, sponsored by NYU Langone Health.
NCT06236087 is a clinical trial that has not yet begun recruiting, run by NYU Langone Health. The registered enrollment target is 500 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06236087 has not yet begun recruiting, sponsored by NYU Langone Health.
- NOT YET RECRUITING
- Registry status
- 500 participants
- Enrollment target
Study Summary
The aims of this study are: (Aim 1) Identify sources of heterogeneous impacts of opioid prevention center (OPC) use on non-fatal and fatal overdose risk among individuals with histories of polysubstance use (PSU); (Aim 2) Estimate the impact of OPC use on treated psychiatric events among clients with histories of PSU, and; (Aim 3) Assess the barriers and facilitators of integrating mental health services into existing syringe service and OPC delivery models.
Primary Outcome
Incidence of fatal overdose will be derived from overdose mortality data from the NYC Office of the Chief Medical Examiner.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2027-09-30 |
What is known before NCT06236087 opens enrollment
NCT06236087 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT06236087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06236087 about?
NCT06236087 is a clinical study titled "Overdose Prevention Centers and Behavioral Health". The aims of this study are: (Aim 1) Identify sources of heterogeneous impacts of opioid prevention center (OPC) use on non-fatal and fatal overdose risk among individuals with histories of polysubstance use (PSU); (Aim 2) Estimate the impact of OPC use on treated psychiatric events among clients wit...
What is the current status of trial NCT06236087?
This trial is currently not yet recruiting. The enrollment target is 500 participants. The study started on 2026-09-01. Estimated completion is 2027-09-30.
Who is sponsoring clinical trial NCT06236087?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI